Growth hormone and glucose metabolism: the model of the GH-receptor - 12/10/17
Resumen |
Pegvisomant is a GH analogue that includes a single amino acid substitution at position 120 that generates the GHR antagonist. Additional changes include amino acid substitutions within binding site 1 and a further modification by the addition of polyethylene glycol moieties that increase the half-life and reduce the immunogenicity of the molecule. In acromegalics, pegvisomant is the most effective treatment for normalizing the IGF-I, and pegvisomant significantly improves insulin sensitivity in patients suffering from acromegaly. However, there are simply no data available that might support a role for pegvisomant treatment in disorders in which glucose metabolism is disturbed and in which reducing GH action would be theoretically beneficial.
El texto completo de este artículo está disponible en PDF.Key words : Growth hormone, pegvisomant, IGF-1, glucose
Esquema
Vol 65 - N° 1
P. 81-83 - février 2004 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.